The science at HIVR4P 2024: The era of choice in biomedical HIV prevention

作者：Beatriz Grinsztejn, Victor Appay, Linda‐Gail Bekker, Chris Beyrer, Deborah Donnell, Jorge Sánchez, Davina Canagasabey, Carolina Coutinho, Yonatan Ganor, Vincent Muturi‐Kioi, Katrina F. Ortblad, Erin E. Cooney, Gastón Devisich, Paula Ellenberg, Yanina Ghiglione, Kevin K'Orimba, Phionah Kibalama Ssemambo, Natasha Ludwig-Barron, Dieter Mielke, Ranajoy Mullick, Michelle K. Muthui, Pablo D. Radusky, Emmanuel Sendaula, Syed Raza Haider Tirmizi, Akemi V. Matsuno Sanchez, Julian Vega, Richard Pebody · 发表于：Journal of the International AIDS Society · 年份：2025 · DOI：10.1002/jia2.70001 · 被引用次数：2 · 研究领域：HIV/AIDS Research and Interventions、HIV, Drug Use, Sexual Risk、Adolescent Sexual and Reproductive Health

INTRODUCTION: HIVR4P 2024, the 5th HIV Research for Prevention Conference, took place in Lima, Peru, 6-10 October 2024. The conference focused on new developments in HIV prevention from basic research to new product development and implementation science. METHODS: Sessions were assigned to one of five tracks: basic science; pre-exposure prophylaxis (PrEP) and antiretroviral (ARV)-based prevention; vaccines and broadly neutralizing antibodies (bNAbs); applied and implementation science; and other prevention modalities and cross-cutting issues. A team of rapporteurs covered each track and identified conference highlights. RESULTS: Strategies to elicit bNAb responses by vaccination are advancing to clinical trials, while combination bNAbs show promise as an alternative to ARV-based products. There is promising diversity in the PrEP product pipeline and twice-yearly lenacapavir has demonstrated exceptional efficacy, but barriers to widespread access and implementation remain, compounded by new challenges from the significant policy changes and funding reductions of the new US administration. Innovative ways of delivering PrEP to vulnerable communities that could benefit are being explored and, in some cases, have been successfully implemented. DISCUSSION: Choice in HIV prevention products and differentiated delivery models that enable clients to select options that meet their preferences and changing needs is essential. Additionally, the involvement of the community throughout th...